Methamphetamine: Difference between revisions
| [unchecked revision] | [pending revision] |
MDElliottMD (talk | contribs) Expand stub to full MedTemplate parameter set |
MDElliottMD (talk | contribs) Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved. |
||
| (11 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Methamphetamine | ||
| brand | | brand = Desoxyn | ||
| structure | | structure = Methamphetamine.svg | ||
| classes | | classes = Psychostimulant, Amphetamine | ||
| | | uses = <vote slug="inattention-meth">Inattention</vote>, <vote slug="hyperactivity-meth">Hyperactivity</vote>, <vote slug="obesity-meth">Obesity</vote> | ||
| | | starting_dose = 5 mg PO | ||
| | | preparations = Desoxyn 5 mg tabs | ||
| | | fda_max = 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) | ||
| routes | | routes = Oral (prescribed) | ||
| onset | | onset = | ||
| duration | | duration = | ||
| halflife | | halflife = | ||
| bioavailability | | bioavailability = | ||
| pregnancy | | pregnancy = Category C (per Desoxyn label) | ||
| legal | | legal = Schedule II | ||
| intro | | mechanism = Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport | ||
| | | intro = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States. | ||
| | | indications = <problem slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/> | ||
| | <problem slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/> | ||
| | | dosing = | effects = | ||
| | * <effect ref="attention" author="MDElliottMD"/> | ||
| | * <effect ref="wakefulness" author="MDElliottMD"/> | ||
| interactions | * <effect ref="motivation" author="MDElliottMD"/> | ||
| pregnancy_details | * <effect ref="euphoria" author="MDElliottMD"/> | ||
| monitoring | * <effect ref="decreased-appetite" author="MDElliottMD"/> | ||
| counseling | * <effect ref="dry-mouth" author="MDElliottMD"/> | ||
| anecdotes | * <effect ref="hr-bp-elevation" author="MDElliottMD"/> | ||
| seealso | * <effect ref="insomnia" author="MDElliottMD"/> | ||
| references | * <effect ref="irritability" author="MDElliottMD"/> | ||
* <effect ref="anxiety" author="MDElliottMD"/> | |||
* <effect ref="headache" author="MDElliottMD"/> | |||
* <effect ref="weight-loss" author="MDElliottMD"/> | |||
* <effect ref="palpitations" author="MDElliottMD"/> | |||
* <effect ref="bruxism" author="MDElliottMD"/> | |||
* <effect ref="stereotypies" author="MDElliottMD"/> | |||
* <effect ref="agitation" author="MDElliottMD"/> | |||
* <effect ref="psychosis" author="MDElliottMD"/> | |||
* <effect ref="mania" author="MDElliottMD"/> | |||
* <effect ref="dependence" author="MDElliottMD"/> | |||
* <effect ref="tolerance" author="MDElliottMD"/> | |||
* <effect ref="cardiac-event" author="MDElliottMD"/> | |||
* <effect ref="seizure" author="MDElliottMD"/> | |||
* <effect ref="hyperthermia" author="MDElliottMD"/> | |||
* <effect ref="serotonin-syndrome" author="MDElliottMD"/> | |||
* <effect ref="withdrawal" author="MDElliottMD"/> | |||
| pk_absorption = | |||
| pk_distribution = | |||
| pk_metabolism = Hepatic metabolism includes N-demethylation to amphetamine (an active metabolite). | |||
| pk_elimination = Urinary elimination is pH-dependent. | |||
| pharmacodynamics = Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition. | |||
| interactions = * '''MAOIs''', contraindicated (per label) | |||
* '''Acidifying agents''', increase urinary clearance | |||
* '''Alkalinizing agents''', decrease urinary clearance | |||
<pharmaInteractions/> | |||
| pregnancy_details = Category C per Desoxyn label. | |||
| monitoring = | |||
| counseling = | |||
| anecdotes = | |||
| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Lisdexamfetamine]], [[Methylphenidate]], [[Dexmethylphenidate]], [[Modafinil]] | |||
| references = <references/> | |||
}} | }} | ||
[[Category:Psychostimulants]] | [[Category:Psychostimulants]] | ||
[[Category:Amphetamines]] | |||
[[Category:Psychostimulants]] | |||
[[Category:Phenethylamines]] | |||
Latest revision as of 03:16, 19 May 2026
Psychostimulant, Amphetamine
Methamphetamine
Desoxyn
Methamphetamine is a CNS stimulant of the amphetamine class. It is FDA-approved (as Desoxyn) for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.
+ Add a problem
Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.
Category C per Desoxyn label.
Mixed amphetamine salts, Dextroamphetamine, Lisdexamfetamine, Methylphenidate, Dexmethylphenidate, Modafinil
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
Obesity (short-term)— 1 don't know
Titration strategies
No titration strategies yet. Be the first to suggest one.
Effects
- Attention and focus no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Wakefulness no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Motivation and drive no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Mild euphoria no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Decreased appetite/Anorexia no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Dry mouth no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Elevated heart rate / blood pressure no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Insomnia no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Irritability no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Anxiety no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Headache no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Weight loss no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Palpitations no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Jaw clenching / bruxism no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Stereotyped behaviors no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Agitation no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Psychosis no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Mania no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Dependence / misuse no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Tolerance no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Serious cardiac event no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Seizure/Epileptic fit no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Hyperthermia no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Serotonin syndrome no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Withdrawal/Discontinuation Syndrome no reports yet no reports yetDid you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
Pharmacokinetics
Metabolism
Hepatic metabolism includes N-demethylation to amphetamine (an active metabolite).Elimination
Urinary elimination is pH-dependent.Pharmacodynamics
Interactions
- MAOIs, contraindicated (per label)
- Acidifying agents, increase urinary clearance
- Alkalinizing agents, decrease urinary clearance
No interactions reported yet.
Pregnancy and lactation
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
See also
References
Pharmacy
Starting dose
5 mg PO
Preparations
Desoxyn 5 mg tabs
US FDA Max
25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label)
Common uses
Structure
Classification(s)
Classes
Psychostimulant, Amphetamine
Pharmacology
Routes
Oral (prescribed)
Pregnancy
Category C (per Desoxyn label)
Legal status
Schedule II
Purported mechanism
Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport